Autres langues Spero Therapeutics, Inc.

Actions

SPRO

US84833T1034

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:49:27 05/10/2026			Varia. 5j.	Varia. 1 janv.
1,155 ^USD	-2,94%		-2,39%	-50,15%

12/08	Transcript : Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
12/08	Spero Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

02/10	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/09	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/09	Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
12/08	Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
07/08	Spero Therapeutics : Initial Statement of Beneficial Ownership (Form 3)
05/08	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/08	Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
27/07	Spero Therapeutics, Inc. Announces Appointment of Debra Jeske Zack as Chief Medical Officer
27/07	Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
15/07	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion
14/07	Innovent Biologics, Inc. and Spero Therapeutics, Inc. Announce Exclusive License Agreement for IBI355, Phase 2-Ready Third-Generation Anti-CD40L Antibody
14/07	Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing
14/07	Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
14/07	Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
14/07	Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Benchmark
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Index
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Index
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index
18/06	MORNING BRIEFING - Deutschland/Europa -2-
17/06	GSK says US FDA approves urinary tract infection treatment Utebzi
17/06	GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections
17/06	GSK Secures US FDA Nod for Complicated Urinary Tract Infection Antibiotic
17/06	GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections